[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Daiichi Sankyo ADR (DSNKY)

Daiichi Sankyo ADR (DSNKY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
1 Biopharma Stock Setting the New Standard in Cancer Care Drugs

The annual conference of the American Society of Clinical Oncology is always the biggest event-making cancer conference. And this year, the attention-grabber was AstraZeneca, as its lung and breast cancer...

AZN : 185.95 (+2.28%)
MS : 211.93 (-2.90%)
DSNKY : 15.3100 (+1.39%)
PFE : 26.04 (+1.36%)
Forget Weight-Loss Drugs, Here's the Next Breakthrough Pharma Stock

There is another segment of the pharma industry that is as hot as weight-loss drugs: antibody-drug conjugates, or ADCs. These treatments will, in the near future, replace conventional chemotherapy, thanks...

AZN : 185.95 (+2.28%)
GMAB : 25.15 (+1.70%)
NVO : 42.96 (-1.81%)
JNJ : 232.77 (+2.02%)
MRK : 120.79 (+0.44%)
DSNKY : 15.3100 (+1.39%)
LLY : 1,131.42 (+0.55%)
ABBV : 227.23 (+1.02%)
RHHBY : 51.4800 (-0.17%)
PFE : 26.04 (+1.36%)
300,000 New Cases: The Role of Biotech in Addressing Rising Breast Cancer Rates

USA News Group – Breast cancer rates are increasing this year, with nearly 300,000 new cases of invasive breast cancer diagnosed in women and 2,800 new cases in men. While breast cancer survival rates...

ONCY : 0.8362 (-3.55%)
AZN : 185.95 (+2.28%)
ARAY : 0.3419 (-6.46%)
DSNKY : 15.3100 (+1.39%)
GILD : 129.16 (-0.02%)
ONC.TO : 1.42 (+2.16%)
Investing in Hope: Biotech Innovations Targeting Increased Breast Cancer Rates in 2023

USA News Group – Breast cancer rates are increasing this year, with nearly 300,000 new cases of invasive breast cancer diagnosed in women and 2,800 new cases in men. While breast cancer survival rates...

ONCY : 0.8362 (-3.55%)
AZN : 185.95 (+2.28%)
ARAY : 0.3419 (-6.46%)
DSNKY : 15.3100 (+1.39%)
GILD : 129.16 (-0.02%)
ONC.TO : 1.42 (+2.16%)
Merck Just Made a Big Move -- but Will It Be Enough for Investors Right Now?

In due time, its new partnership with Daiichi Sankyo could be massive.

MRK : 120.79 (+0.44%)
DSNKY : 15.3100 (+1.39%)
Is Gilead Sciences a Good Stock to Buy Now?

Gilead Sciences' breast cancer drug, Trodelvy, just took a big step forward.

AZN : 185.95 (+2.28%)
DSNKY : 15.3100 (+1.39%)
GILD : 129.16 (-0.02%)
PFE : 26.04 (+1.36%)

Barchart Exclusives

Greg Abel is Writing Checks for Berkshire Hathaway in a Hurry. You Should Write One for BRK.B Stock.
Berkshire Hathaway has announced investments worth $16.8 billion over the last few days, as CEO Greg Abel tries to put the conglomerate's massive cash pile to work. Is it time to buy BRK.B stock? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.